Radiopharmaceutical developer Mallinckrodt Medical said that itwill begin sales in Sweden of TechneScan Q12, a technetium-basedcardiac imaging agent, following approval of the agent by Sweden'shealth authorities. Sweden is the first country in the
Radiopharmaceutical developer Mallinckrodt Medical said that it
will begin sales in Sweden of TechneScan Q12, a technetium-based
cardiac imaging agent, following approval of the agent by Sweden's
health authorities. Sweden is the first country in the European
Union to approve TechneScan, and certifications in other European
nations are expected. St. Louis-based Mallinckrodt filed a new
drug application for the product in the U.S. in 1994.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.